In the German market, Salmex will be available under the trade name Salflutin. After completing the DCP registration procedure, the German drug registration authority will verify the national version of the information materials (including the leaflet, the medicine package) and will issue a final decision on marketing authorisation within the time limits set by the German legislative procedure, i.e. approx. 3 months. The time when the product will be marketed depends on the time of obtaining the final marketing authorisations and is estimated to be the fourth quarter of 2018.The market of the reference drug in Germany is around 3.5 million inhalers annually, which is very important from the point of view of the Company's export plans.
The conclusion of the DCP is the result of the Company’s consistent strategy in terms of expansion to foreign markets.